Equities

2cureX AB

2cureX AB

Actions
  • Price (SEK)0.47
  • Today's Change0.031 / 7.06%
  • Shares traded42.98k
  • 1 Year change-93.29%
  • Beta0.4532
Data delayed at least 15 minutes, as of Apr 25 2024 17:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

2cureX AB is a Sweden-based company engaged in the biotechnology sector. The Company focuses on the research and development of diagnostic substances to select treatment for cancer patients. The Company's product candidate, IndiTreat - CRC, aims at optimizing medical treatment for the colorectal cancer patients. Through IndiTreat - CRC, healthcare professionals collect a tumor sample from patients to create a number of three-dimensional micro tumors in order to test available chemotherapies and experimental treatments. The Company's product pipeline includes also IndiTreat - OVA, targeting ovarian cancer treatment, and IndiTreat - KDN, focusing on kidney cancer treatment. It operates through 2cureX A/S.

  • Revenue in SEK (TTM)155.00k
  • Net income in SEK-30.82m
  • Incorporated2017
  • Employees--
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Redwood Pharma AB0.00-14.18m3.13m1.00--0.2305-----9.25-9.250.005.120.00----0.00-86.77-95.03-98.20-123.04-----------19.99---------8.78---5.11--
XP Chemistries AB663.69k-8.04m3.46m2.00--0.1346--5.21-0.2846-0.28460.02130.2750.0230.20845.99331,845.00-27.79---29.36--50.57---1,211.24--5.79--0.00---37.14---1.55------
European Institute of Science AB600.00k-2.72m5.09m0.00--1.26--8.49-4.25-4.250.93972.980.17280.84798.63---78.21-93.04-82.77-103.1462.3367.01-452.67-518.8210.54------13.698.540.4062------
QuiaPEG Pharmaceuticals Holding AB0.00-16.52m5.61m8.00--0.3678-----3.51-3.510.000.20470.00-------50.53-95.67-100.54-207.86--262.59---5,002.50---15.340.00------17.75--47.06--
Lipidor AB77.00k-11.49m6.66m--------86.55-0.3964-0.39640.0027-0.32230.0084--5.31---124.54-59.41---75.10-----14,916.88-643.36--------73.33-20.3372.24------
Bio Vitos Pharma AB2.98m-12.87m6.72m1.00--1.7513.092.25-0.2547-0.25470.05330.11190.09890.005.382,983,990.00-42.63-31.11-44.50-32.92100.00---431.21-1,026.764.27--0.00--126.97--13.64------
2cureX AB155.00k-30.82m7.73m----0.5645--49.86-1.75-1.750.00880.77770.0048--0.0838---95.89-38.21-108.66-43.48-6,889.68-22,153.06-19,883.23-38,685.30---46.08----72.22---3.52------
Stayble Therapeutics AB0.00-23.74m7.91m3.00--0.4794-----0.9492-0.94920.000.52040.00----0.00-116.21-78.64-141.76-95.58------------0.049------3.22------
Carbiotix AB (publ)1.47m-13.48m10.13m10.00--0.1473--6.91-0.302-0.3020.03240.38170.0586--2.36146,552.00-53.88-49.38-64.85-55.50235.45574.69-919.76-1,828.86---76.280.1384--259.56-12.04-10.02--13.64--
Amniotics AB (publ)0.00-30.87m10.66m6.00--0.6803-----0.0374-0.03740.000.00570.00----0.00-112.25-101.09-362.71-149.92--------1.12-16.17--------35.75------
Lidds AB0.00-40.21m11.12m2.00--0.8002-----0.7253-0.72530.000.20370.00----0.00-184.53-46.33-274.92-51.61-------3,076.68---------100.00---9.08------
Data as of Apr 25 2024. Currency figures normalised to 2cureX AB's reporting currency: Swedish Krona SEK
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.